AZNCF News and Press, AstraZeneca Plc From 11/15/21

The following slide deck was published by AstraZeneca PLC in conjunction with their 2021 Q3 earnings call. For further details see: AstraZeneca PLC 2021 Q3 - Results - Earnings Call Presentation

AstraZeneca PLC (AZN) Q3 2021 Earnings Conference Call November 12, 2021, 6:45 AM ET Company Participants Pascal Soriot – CEO Chris Sheldon – Head of Investor Relations Aradhana Sarin – Chief Financial Officer Dave Fredrickson – Executive Vice-President, Oncology B...

VYMI strategy and portfolio. Past performance vs. competitors. Takeaway. For further details see: VYMI: International High Yield Overweight In Financials

Moderna's stock is getting crushed again today, now down substantially in back-to-back sessions. In fact, the company's shares are now down by more than 50% from the company's ATH. Despite recent "setbacks," Moderna remains a company with exceptional potential. Have you seen t...

Weaker earnings and guidance are pushing shares down. Greater competition means lower profitability in the future. Moderna's pipeline will never be as valuable as its Covid-19 drugs. Shares could fall between $115 and $190. For further details see: Moderna's Stock Wi...

Fisher’s 13F portfolio value increased from ~$159B to ~$161B in Q3 2021. Advanced Micro Devices, Facebook, and Lam Research were increased while reducing Visa this quarter. The top three positions are Apple, Microsoft, and Amazon. They add up to ~14% of the portfolio. ...

Comirnaty vaccination now involves between two and four separate treatments, a substantial increase on the initial two-dose vaccination schedule. Comirnaty is the vaccine of choice for 12-18-year-olds and 5-11 vaccination is coming (with 6 months - 5 to follow). Pfizer CEO is read...

Moderna is the most effective COVID-19 vaccine, based on the latest CDC data. Moderna has applied for full approval from the US FDA and is awaiting its EUA for booster shots. Novavax has filed for EUL from WHO and expects to file for EUA from the US FDA in Q4'21. Moderna has 1...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

The following slide deck was published by AstraZeneca PLC in conjunction with this event. For further details see: AstraZeneca <<AZN>> presents at ESMO 2021Virtual Congress - slideshow